Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 872 results for "novartis"

Driven By Pfizer Inc. And Novartis AG (ADR), Global Breast Can...

Global breast cancer branded drug sales may rise to $20 billion in 2020, compared to $13 billion reported in 2014, as per consensus data compiled by Bloomberg Intelligence, which only takes into account currently approved drugs. Roche Holding Ltd. Bidness Etc, 1 day ago

93 images for novartis

Philippine Daily Inquirer, 2 days ago
European Pharmaceutical Review, 2 days ago
EuroInvestor, 4 days ago
EuroInvestor, 4 days ago
Reuters, 2 weeks ago
Business Standard, 1 week ago
NDTV Profit, 3 weeks ago
OncLive, 2 weeks ago
Philippine Daily Inquirer, 3 weeks ago
InvestorPlace.com, 3 weeks ago
Motley Fool

Will Competition Cause Teva Pharmaceutical Industries ltd. To Tumble?

Last month, the Food and Drug Administration gave the go-ahead to Novartis' (NYSE: NVS Glatopa's approval helps clear the way for generic versions of other biologic drugs, which are known as biosimilars because they aren't exact copies. Since this ...
 Motley Fool1 day ago
EuroInvestor

Novartis announces positive results from phase III study of Afinitor in advanced GI/lung neuroendocrine tumours

Novartis announced that the phase III study of Afinitor (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumours (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant ...
 PharmaBiz2 days ago Novartis announces two positive US phase III programmes in COPD for QVA149 and NVA237  CPhI.cn1 hour ago Novartis' Afinitor successful in Phase 3 study for expanded indication  Seeking Alpha3 days ago Novartis' duo of COPD drugs clears Phase III on the path to an FDA decision  FierceBiotech2 days ago
[x]  

Novartis' Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel

Entresto . That's the brand name Novartis has chosen for LCZ696, itsnew heart failure drug that is expected tobe a blockbuster. The name won't be finaluntil official confirmation, which comes withFDA approval. But Novartis will introducethe name for ...
 Forbes.com2 days ago Novartis' LCZ696 Gains Name, Skips Advisory Panel  Forbes.com2 days ago
Philippine Daily Inquirer

Transforming the way people live with cancer

(First in a series) KETCHUM Research-based Swiss healthcare company Novartis considers Asia an important market. Asia is home to 60 percent of the world population. Almost half of all new cancer cases and slightly more than half of all cancer ...
 Philippine Daily Inquirer2 days ago

CSL Gains Flu-Vaccine Scale With Novartis Deal: Perreault

Paul Perreault, chief executive officer for CSL Behring LLC, talks about the acquisition of Novartis AG's influenza vaccination business and growth strategy. Perreault speaks with Erik Schatzker and Stephanie Ruhle on Bloomberg Television's ...
 Bloomberg2 days ago

Novartis Set to Possibly Pullback After Yesterday's Rally of 1.25%

Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $104.25 to a high of $105.10. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $104.55 on volume of 1.4 million shares. Often times ...
 Individual.com3 days ago

Stock Investors Bid Up Shares of Novartis, Up 1.2%

One of today's stocks on the move is Novartis (NYSE:NVS), up 1.4% to $104.94. The S&P is currently trading 0.3% higher to 2,132 and the Dow Jones Industrial Average is trading fractionally higher
 Individual.com3 days ago

BRIEF-Novartis says lung disease drug studies show positive results

* Novartis says it saw positive results from two Phase III clinical trial programs for QVA149 and NVA237 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) * The Swiss drugmaker said data demonstrated QVA149, ...
 Reuters4 days ago Studies from Novartis Pharma Provide New Data on Clinical Trials and Studies (Ultrafast quantitative MS-based method for ceritinib analysis in human...  4 Traders4 days ago Arrowhead buys Novartis’ RNAi portfolio  Reuters2 months ago

Novartis AG (NVS) Showing Bullish Technicals With Resistance At $104.50

May 20, 2015 (Marketintelligencecenter.com via COMTEX News Network) -- Novartis AG ( NVS ) traded between $103.71 and $104.28 before closing at $103.80 Tuesday and presents some attractive trading opportunities today.
 PredictWallStreet4 days ago Potential Novartis AG (NVS) Trade Has 6.27% Downside Protection  Individual.com6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less